Author:
Britt Rachel S.,Evoy Kirk E.,Lee Grace C.,Reveles Kelly R.,Sorensen Kimberly M.,Jones Xavier,Bollinger Mary,Frei Christopher R.
Funder
Allergan
National Center for Advancing Translational Sciences
National Institute on Aging
Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Antibiotic resistance threats in the United States, 2013. Atlanta: United States Centers for Disease Control and Prevention (CDC); 2013.
http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf
. Last accessed 26 Sept 2016.
2. Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51:641–50.
3. Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl 3):iii53–9.
4. Teflaro Package Insert, US Food and Drug Adminstration. 2016.
http://www.allergan.com/assets/pdf/teflaro_pi
. Last accessed 26 Sept 2016.
5. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS 2nd. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012;67:1267–70.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献